Type I interferon in the pathogenesis of lupus
MK Crow - The Journal of Immunology, 2014 - journals.aai.org
Investigations of patients with systemic lupus erythematosus have applied insights from
studies of the innate immune response to define IFN-I, with IFN-α as the dominant mediator …
studies of the innate immune response to define IFN-I, with IFN-α as the dominant mediator …
The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus
MD Catalina, KA Owen, AC Labonte, AC Grammer… - Journal of …, 2020 - Elsevier
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease that causes
damage to multiple organ systems. Despite decades of research and available murine …
damage to multiple organ systems. Despite decades of research and available murine …
Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression
Trait-associated genetic variants affect complex phenotypes primarily via regulatory
mechanisms on the transcriptome. To investigate the genetics of gene expression, we …
mechanisms on the transcriptome. To investigate the genetics of gene expression, we …
[HTML][HTML] Trial of anifrolumab in active systemic lupus erythematosus
Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
D Jayne, B Rovin, EF Mysler, RA Furie… - Annals of the …, 2022 - ard.bmj.com
Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
M Khamashta, JT Merrill, VP Werth, R Furie… - Annals of the …, 2016 - ard.bmj.com
Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb,
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
GI Rice, PR Kasher, GMA Forte, NM Mannion… - Nature …, 2012 - nature.com
Adenosine deaminases acting on RNA (ADARs) catalyze the hydrolytic deamination of
adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the …
adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the …
Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus
Neutrophil dysregulation is implicated in the pathogenesis of systemic lupus erythematosus
(SLE). SLE is characterized by elevated levels of a pathogenic neutrophil subset known as …
(SLE). SLE is characterized by elevated levels of a pathogenic neutrophil subset known as …